OCMO
OCMO
Share
Office of the Chief Medical Officer

Scientific Excellence, Bioethics and Values-Driven Decision-Making

Share
Today's Top Reads Close

The Office of the Chief Medical Officer (OCMO) is a global, functionally independent group responsible for leading medical safety and championing bioethical principles across Johnson & Johnson’s Pharmaceutical, Medical Device and Consumer Health sectors. Johnson & Johnson’s OCMO is constantly reviewing, monitoring and making decisions regarding the safety of our products through people-driven processes, initiatives and policies that are reinforced by a single medical safety standard, to which all our products are held.

At the heart of OCMO is our responsibility for leading difficult decision-making regarding the medical safety of our products while always keeping the best interests of patients and consumers at the center of everything we do.

Our focus is to provide safe products for the people who use them; advancing evidence- and science-based decision-making, so that patient safety always comes first in every decision that we make as a company; and being a champion for initiatives and policies that allow us to listen to and learn from patients.


We have created new standards in collaboration with the research community to share clinical data to instill confidence and to advance public health. We’ve raised the bar in the area of compassionate use by providing a fair, objective, transparent and ethical evaluation for every patient request for investigational medicines. In addition, we’ve helped to highlight the importance of pediatric clinical research to ensure we are meeting the unique needs of children.

We also work to make sure decisions at Johnson & Johnson are guided by a framework of bioethical principles and values, so that in addition to being patient-centered, we also remain fair, transparent and respectful of the rights and welfare of all people.

A commitment to bioethics has been especially important during the COVID-19 pandemic. That is why Johnson & Johnson’s Office of the Chief Medical Officer, in collaboration with internal and external experts, developed an ethical framework to guide our decision-making during the COVID-19 pandemic.

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue